article thumbnail

Optimal antithrombotic therapy after transcatheter aortic valve replacement: a comprehensive review

Frontiers in Cardiovascular Medicine

Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.

article thumbnail

Major Win for Preemptive TAVR in Symptomless Aortic Stenosis

Med Page Today

(MedPage Today) -- Transcatheter aortic valve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aortic valve replacement, according to the EARLY TAVR.

TAVR 105
article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.

TAVR 111
article thumbnail

Caution Raised for Post-TAVR Cardiac Surgeries

Med Page Today

(MedPage Today) -- SAN ANTONIO -- The early experience of patients needing cardiac surgery after transcatheter aortic valve replacement (TAVR) has surgeons raising the alarm about the excess risks of these challenging procedures, based on data.

TAVR 135
article thumbnail

Valvular and perivalvular thrombus after TAVR: Risks and Outcomes

Cardiology Update

Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex. Specifically, 14.2%

TAVR 122
article thumbnail

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.

article thumbnail

New Study Finds Mechanical Valves Offer Superior Long-Term Survival for Aortic Valve Replacement Patients Aged 60 and Younger

Society of Thoracic Surgeons - Congenital

The decision between a bioprosthetic and mechanical valve is one of the most consequential for patients requiring aortic valve replacement, said Michael Bowdish, MD, lead author of the study and a cardiothoracic surgeon at Cedars-Sinai Medical Center in Los Angeles.